Vaxart announced it will host a key opinion leader video webcast on the health and economic impact and disease burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET. The webcast will feature presentations by prominent norovirus disease experts Jan Vinje, Ph.D., Head, National Calicivirus Laboratory, Centers for Disease Control & Prevention, and Sarah Bartsch, Project Director, Public Health Informatics, Computational, and Operations Research, Research Foundation of the City University of New York. In addition, Vaxart management will provide a detailed overview of the Company’s investigational norovirus oral pill vaccine program, including its two current Phase 2 clinical trials: An ongoing Phase 2 GI.1 norovirus challenge study measuring the efficacy and safety of our norovirus vaccine candidate. The study is also designed to identify a correlate of protection between immune responses to the vaccine and a reduction in risk of norovirus infection and / or severe gastroenteritis. The Company expects to report topline data from this study in Q3 2023. A Phase 2 dose-ranging study of Vaxart’s bivalent norovirus oral vaccine candidate is designed to identify a vaccine dose for a potential Phase 3 clinical trial. The Company expects to report topline data from this study in mid-2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VXRT:
- Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
- Vaxart Provides Business Update and Full Year 2022 Financial Results
- Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
- Vaxart options imply 40.1% move in share price post-earnings
- Vaxart options imply 39.1% move in share price post-earnings